News | October 16, 2023
ImmunoACT announces the approval of India's first CAR-T cell therapy 'NexCAR19'
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
This fresh infusion of capital will enable ImmunoACT to fast track the additional supply of the lead candidate HCAR-19
ImmunoACT has a portfolio of CAR-T therapy assets under various development stages for the treatment of multiple autoimmune diseases and oncology indications.
GlobalData’s ‘Pharmaceutical Intelligence Center’ observes that India is still in the nascent stage of developing these potential therapies as currently only four cell/gene therapy molecules are being developed in the country.
Subscribe To Our Newsletter & Stay Updated
